Sensitivity to brentuximab vedotin depends on CD30-expression levels in different subtypes of cutaneous T-cell lymphoma cell lines

被引：0
|
作者：
Hofer, V. [1 ]
Wobser, M. [1 ]
Maurus, K. [2 ]
Houben, R. [1 ]
Schrama, D. [1 ]
机构：
[1] Uniklinikum Wurzburg, Wurzburg, Germany
[2] Univ Wurzburg, Pathol, Wurzburg, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
eP105
引用
收藏
页码：92 / 92
页数：1
相关论文
共 50 条
  • [41] Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: a single-centre retrospective review
    Berg, M. -H. Henderson
    Davison, K.
    Popradi, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (02) : 379 - 381
  • [42] Brentuximab vedotin in the treatment of relapsed/refractory CD30+peripheral T-cell lymphoma: A FIL phase 2 study
    Stefoni, Vittorio
    Pellegrini, Cinzia
    Argnani, Lisa
    Corradini, Paolo
    Dodero, Anna
    Orsucci, Lorella
    Volpetti, Stefano
    Zinzani, Pier Luigi
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (02) : 307 - 309
  • [43] Successful Treatment of an Aggressive Adult T-cell Leukemia/Lymphoma with Strong CD30 Expression Using Brentuximab Vedotin as Combination and Maintenance Therapy
    Baba, Yuta
    Sakai, Hirotaka
    Kabasawa, Nobuyuki
    Harada, Hiroshi
    INTERNAL MEDICINE, 2023, 62 (03) : 613 - 616
  • [44] Frontline brentuximab vedotin in Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphoma for older patients and those with comorbidities.
    Yasenchak, Christopher A.
    Bordoni, Rodolfo Eduardo
    Yazbeck, Victor Y.
    Patel-Donnelly, Dipti
    Larson, Tim
    Sims, Robert Brownell
    Mei, Matthew Genyeh
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [45] Cutaneous T-Cell Lymphomas - under targeted Therapy with Brentuximab Vedotin and Mogamulizumab
    Bartels, P.
    Debus, D.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 51 - 51
  • [46] Growth dynamics and cyclin expression in cutaneous T-cell lymphoma cell lines
    Biskup, Edyta
    Manfe, Valentina
    Kamstrup, Maria
    Gniadecki, Robert
    DERMATOLOGY REPORTS, 2010, 2 (01) : 21 - 22
  • [47] Efficacy and safety of Brentuximab Vedotin in advanced cutaneous T-Cell lymphomas patients
    Papadavid, E.
    Kapniari, E.
    Marinos, L.
    Nikolaou, V.
    Oikonomidi, A.
    Georgakopoulos, J.
    Stratigos, A.
    Kouloulias, V.
    Pappa, V.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (05) : E223 - E225
  • [48] Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study
    Kim, Y. H.
    Whittaker, S.
    Horwitz, S. M.
    Duvic, M.
    Dummer, R.
    Scarisbrick, J.
    Quaglino, P.
    Zinzani, P.
    Wolter, P.
    Wang, Y.
    Palanca-Wessels, M.
    Zagadailov, E.
    Trepicchio, W. L.
    Lin, H.
    Little, M.
    Prince, H.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S45 - S45
  • [49] Management of ALCL and other CD30+peripheral T-cell lymphomas with a focus on Brentuximab vedotin
    Nizamuddin, Imran
    Galvez, Carlos
    Pro, Barbara
    SEMINARS IN HEMATOLOGY, 2021, 58 (02) : 85 - 94
  • [50] Differential CD30 expression in adult T-cell leukemia-lymphoma subtypes
    Germán Campuzano-Zuluaga
    Agustin Pimentel
    Jennifer R Chapman-Fredricks
    Juan Carlos Ramos
    Retrovirology, 11 (Suppl 1)
12345